Specific pharmacological inhibition of KDM5A by YUKA1 or KDM5-inh1 significantly reduces resistance to trastuzumab and lapatinib in HER2-positive BC (Gale et al., 2016; Paroni et al., 2019). Here, ERBB2 is linked to breast cancer.